XML 40 R29.htm IDEA: XBRL DOCUMENT v3.22.1
Investments and Fair Value Measurements - Narrative (Details)
3 Months Ended
Aug. 18, 2021
USD ($)
Apr. 25, 2019
Apr. 03, 2022
USD ($)
fund
Apr. 04, 2021
USD ($)
Mar. 31, 2020
USD ($)
Dec. 29, 2019
USD ($)
Jan. 02, 2022
USD ($)
Feb. 28, 2021
USD ($)
Jan. 02, 2020
USD ($)
Schedule of Investments [Line Items]                  
Marketable equity securities     $ 65,000,000       $ 107,000,000    
Strategic equity investments, without readily determinable fair values     41,000,000       40,000,000    
Gain on Helix contingent value right     5,000,000 $ 10,000,000          
Gain on derivative assets related to terminated acquisition     0 26,000,000          
Pacific Biosciences of California, Inc (PacBio)                  
Schedule of Investments [Line Items]                  
Cash         $ 34,000,000 $ 18,000,000      
Business combination, contingent consideration arrangements, maximum outcome                 $ 52,000,000
Equity or debt financing to be raised                 $ 100,000,000
GRAIL Inc                  
Schedule of Investments [Line Items]                  
Contingent value right, terms 12 years                
GRAIL Inc | Payment Rights Of One Billion, Each Twelve Years                  
Schedule of Investments [Line Items]                  
Contingent payment rights, percentage 2.50%                
Business acquisition, contingent value rights, revenue threshold $ 1,000,000,000                
GRAIL Inc | Payment Rights Of Above One Billion, Each Twelve Years                  
Schedule of Investments [Line Items]                  
Business acquisition, contingent value rights, revenue threshold $ 1,000,000,000                
Contingent payment rights, second percentage 9.00%                
Helix Holdings I, LLC                  
Schedule of Investments [Line Items]                  
Contingent value right, terms   7 years              
Gain on Helix contingent value right     $ 5,000,000 10,000,000          
Pacific Biosciences of California, Inc (PacBio) | S B Northstar L P                  
Schedule of Investments [Line Items]                  
Business combination, contingent consideration arrangements, maximum outcome               $ 52,000,000  
Gain on derivative assets related to terminated acquisition       26,000,000          
Pacific Biosciences of California, Inc (PacBio) | S B Northstar L P | Convertible Senior Notes                  
Schedule of Investments [Line Items]                  
Principal amount of notes outstanding               $ 900,000,000  
Venture Capital Investment Fund (the Fund)                  
Schedule of Investments [Line Items]                  
Number of venture capital investment funds | fund     2            
Equity method investments     $ 183,000,000       $ 173,000,000    
Unrealized gain (loss) on investments     (2,000,000) 33,000,000          
Venture Capital Investment Fund (the Fund), One                  
Schedule of Investments [Line Items]                  
Commitment in new venture capital investment fund     100,000,000            
Remaining capital commitment     14,000,000            
Venture Capital Investment Fund (the Fund), Two                  
Schedule of Investments [Line Items]                  
Commitment in new venture capital investment fund     150,000,000            
Remaining capital commitment     110,000,000            
Investee                  
Schedule of Investments [Line Items]                  
Revenue from transactions with strategic investees     $ 30,000,000 $ 13,000,000